R
Radhika Gogoi
Researcher at Geisinger Medical Center
Publications - 47
Citations - 471
Radhika Gogoi is an academic researcher from Geisinger Medical Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 10, co-authored 30 publications receiving 361 citations. Previous affiliations of Radhika Gogoi include New York University & Lankenau Medical Center.
Papers
More filters
Journal ArticleDOI
DNA nanotherapy for pre-neoplastic cervical lesions.
Weidan Peng,Charles Dunton,Charles Dunton,David Holtz,David Holtz,Mehdi Parva,Kate Stampler,Mark Forwood,Radhika Gogoi,Radhika Gogoi,Michael J. Lace,Michael J. Lace,Daniel G. Anderson,Janet A. Sawicki,Janet A. Sawicki +14 more
TL;DR: An HPV16 DNA sequence that targets gene expression specifically to HPV16-infected cells remains to be discovered, and topical application of a Lutrol F127 thermal gel/nanoparticle mix is illustrative of how to restrict exposure of cells to therapeutic nanoparticles, thereby allowing for targeted DNA delivery to cervical pre-cancerous lesions.
Journal ArticleDOI
Evaluation of Society of Gynecologic Oncologists (SGO) ovarian cancer quality surgical measures
TL;DR: This study sets benchmarks for evaluation of documentation in gynecologic oncology centers and shows that improved documentation and staging will allow for equivalent standards of care across institutions.
Journal ArticleDOI
Differential gene expression induced by Verteporfin in endometrial cancer cells.
TL;DR: RNA sequencing data revealed multiple key genes of pathological significance in EMCA, thereby improving the understanding of molecular profiles of EMCA cells and indicating that subcutaneous tumors in mice were regressed after VP treatment by inhibiting cell cycle pathway proteins.
Journal ArticleDOI
The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion.
TL;DR: Although classified as a progestin, medroxyprogesterone acetate has significant androgenic activity unique from the pure androgen dihydrotestosterone, and these studies suggest that pharmacologic doses of medroxy Prozac may actually increase the invasive potential of epithelial ovarian cancer cells.
Journal ArticleDOI
Randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer: The Women’s Activity and Lifestyle Study in Connecticut (WALC).
Yang Zhou,Linda Gottlieb,Brenda Cartmel,Fangyong Li,Elizabeth Ercolano,Maura Harrigan,Ruth McCorkle,Jennifer A. Ligibel,Vivian E. von Gruenigen,Radhika Gogoi,Peter E. Schwartz,Harvey A. Risch,Melinda L. Irwin +12 more
TL;DR: This study randomized 144 physically inactive ovarian cancer survivors who had completed initial chemotherapy into a 6 month RCT of exercise vs. attention control and measured HRQOL and fatigue in Ovarian cancer survivors.